Protagonist Therapeutics (PTGX) Cash from Operations (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Cash from Operations of 48943000.0 for Q1 2026, down 139.04% on a YoY basis from 125363000.0 in Q1 2025, and down 32.37% sequentially from 36975000.0 in Q4 2025.
Protagonist Therapeutics (PTGX) Cash from Operations (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Cash from Operations data on file, last reported at 48943000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 139.04% year-over-year to 48943000.0; the trailing twelve-month figure through Mar 2026 stood at 116635000.0 (down 134.62% YoY), and the FY2025 full-year result was 57671000.0, down 68.68% from the prior year.
- Cash from Operations fell to 48943000.0 in Q1 2026, from 36975000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 268622000.0 in Q2 2024 to a low of 48943000.0 in Q1 2026.
- A 5-year average of 853352.94 and a median of 27429000.0 in 2024 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 1123.79% in 2024, while the deepest fall reached 272.04% in 2024.
- Tracing PTGX's Cash from Operations over 5 years: stood at 31635000.0 in 2022, then surged by 153.61% to 16960000.0 in 2023, then plunged by 272.04% to 29178000.0 in 2024, then fell by 26.72% to 36975000.0 in 2025, then slumped by 32.37% to 48943000.0 in 2026.
- Business Quant data shows PTGX's Cash from Operations at 48943000.0 in Q1 2026, 36975000.0 in Q4 2025, and 1937000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -48.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.94 Mn |
| Mar 31, 2026 | -48.94 Mn |
| Dec 31, 2025 | -36.98 Mn |
| Dec 31, 2025 | -36.98 Mn |
| Sep 30, 2025 | -1.94 Mn |
| Sep 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Mar 31, 2025 | 125.36 Mn |
| Mar 31, 2025 | 125.36 Mn |
| Dec 31, 2024 | -29.18 Mn |
| Dec 31, 2024 | -29.18 Mn |
| Sep 30, 2024 | -27.86 Mn |
| Sep 30, 2024 | -27.86 Mn |
| Jun 30, 2024 | 268.62 Mn |
| Jun 30, 2024 | 268.62 Mn |
| Mar 31, 2024 | -27.43 Mn |
| Mar 31, 2024 | -27.43 Mn |
| Dec 31, 2023 | 16.96 Mn |
| Dec 31, 2023 | 16.96 Mn |